AI
By
Is Aidoc’s $150M Bet on CARE™ and aiOS™ Resetting the Future of Clinical AI for 100 Million Patients?
Key Highlights CARE™ Foundation Model Redefining Standards in Clinical AIAidoc’s CARE™ model—now backed by $150 million in new…
Can Mandolin’s $40M VC Boost End Insurance Delays and Accelerate Access to Specialty Medications? What This Means for AI in Healthcare Delivery
Key Highlights: AI-Driven Innovation Tackling a Complex Healthcare BarrierSpecialty medications for cancer and neurodegenerative diseases often require authorization…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Is Mayo Clinic’s NVIDIA Blackwell-Powered DGX SuperPOD the Next Leap in AI-Driven Clinical Innovation?
Key Highlights NVIDIA Blackwell Infrastructure: High-Performance Compute for Healthcare AIThe NVIDIA DGX SuperPOD system delivers state-of-the-art, scalable AI…
Is Aptitude’s $9M BARDA Partnership and Metrix Filovirus Panel the Breakthrough for Fast, Decentralized Detection of Ebolavirus and Marburgvirus?
Key Highlights BARDA Partnership Accelerates Filovirus Diagnostic InnovationAptitude’s second collaboration with BARDA brings $9 million in new federal…
